Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 4, 2011, Pages 541-549

  Song, Yao Hong ^a   Cai, Hui ^b   Gu, Ning ^a   Qian, Chun Fa ^a   Cao, Shou Pei ^a   Zhao, Zhi Ming ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

Cardiac remodelling; Congestive heart failure; Icariin; Matrix metalloproteinase; Myocardial apoptosis

Indexed keywords

ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; GELATIN; GELATINASE A; GELATINASE B; ICARIIN; ISOPRENALINE; MESSENGER RNA; NORADRENALIN; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CELL DEGENERATION; CELL STRUCTURE; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART RATE; INFLAMMATORY INFILTRATE; MALE; MORPHOMETRICS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ZYMOGRAPHY;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FLAVONOIDS; HEART FAILURE; HEMODYNAMICS; ISOPROTERENOL; MALE; MATRIX METALLOPROTEINASES; MITOCHONDRIA; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 79952727485     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01241.x     Document Type: Article

References (44)

1. Hartmann RW et al. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur J Med Chem 2003; 38: 363-366. (Pubitemid 36577187)
2. Brower GL et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardio-Thoracic Surg 2006; 30: 604-610. (Pubitemid 44332949)
3. Dhalla NS et al. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Ther 2006; 11: 31-45.
4. Takai S et al. Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters. Eur J Pharmacol 2007; 568: 231-233. (Pubitemid 46976911)
5. Morita H et al. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol 2006; 290: H2522-H2527. (Pubitemid 43846083)
6. Batlle M et al. Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients. Transplant Proc 2007; 39: 2344-2346. (Pubitemid 47418155)
7. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80: L26-L40.
8. Dixon IMC et al. Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem 1996; 165: 31-45. (Pubitemid 26421348)
9. Francis GS, Tang WHW. Early cardiac resynchronization therapy and reverse remodeling in patients with mild heart failure is it time? Circulation 2009; 120: 1845-1846.
10. Ye L-C, Chen J-M. Advances in study on pharmacological effects of epimedium. Zhongguo Zhongyao Zazhi 2001; 26: 293-295.
11. Huang X-L et al. Protective effect of epimedium flavonoids injection on experimental myocardial infarction rats. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006; 26: 68-71.
12. Pan Y et al. Icariin from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats. Pharmacol Biochem Behav 2007; 87: 130-140. (Pubitemid 46855827)
13. Xu HB, Huang ZQ. Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol 2007; 47: 18-24.
14. He W et al. Immunoregulatory effects of the herba Epimediia glycoside icariin. Arzneimittelforschung 1995; 45: 910-913.
15. Yang JX et al. Anti-proliferative efficacy of icariin on HepG2 hepatoma and its possible mechanism of action. Am J Chin Med 2009; 37: 1153-1165.
16. Zhao J et al. Icariin induces osteogenic differentiation in vitro in a BMP- and Runx2-dependent manner. Biochem Biophys Res Commun 2008; 369: 444-448.
17. Ding L et al. Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro. Stem Cells Dev 2008; 17: 751-760.
18. Teerlink JR et al. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994; 75: 105-113.
19. Torimura T et al. Laminin deposition to type IV collagen enhances haptotaxis, chemokinesis, and adhesion of hepatoma cells through beta 1-integrins. J Hepatol 2001; 35: 245-253. (Pubitemid 32803480)
20. Calvino-Fernandez M et al. Oxidative stress by Helicobacter pylori causes apoptosis through mitochondrial pathway in gastric epithelial cells. Apoptosis 2008; 13: 1267-1280.
21. Appierto V et al. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 2009; 30: 824-831.
22. Chauhan D et al. Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene 2003; 22: 6296-6300. (Pubitemid 37281659)
23. Gazoti Debessa CR et al. Age related changes of the collagen network of the human heart. Mech Ageing Dev 2001; 122: 1049-1058. (Pubitemid 32520990)
24. Beltrami CA et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994; 89: 151-163. (Pubitemid 24026485)
25. Muller-Ehmsen J, Schwinger RHG. TNF and congestive heart failure: Therapeutic possibilities. Expert Opin Ther Targets 2004; 8: 203-209. (Pubitemid 38885644)
26. Swedberg K et al. Effects of sustained-release moxonidine, an imidazoline agonist on plasma norepinephrine in patients with chronic heart failure. Circulation 2002; 105: 1797-1803. (Pubitemid 34408889)
27. Lage SG et al. Angiotensin II contributes to arterial compliance in congestive heart failure. Am J Physiol Heart Circ Physiol 2002; 283: H1424-H1429.
28. Adams KF Jr et al. Biomarker guided therapy for heart failure: focus on natriuretic peptides. Heart Fail Rev 2009; 3: 1382-4147.
29. Rohde LE et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99: 3063-3070. (Pubitemid 29270438)
30. Iwanaga Y et al. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39: 1384-1391. (Pubitemid 34297882)
31. Sakata Y et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-2149. (Pubitemid 38620225)
32. Peterson JT et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001; 103: 2303-2309. (Pubitemid 32433722)
33. Spinale FG et al. A matrix metalloproteinase induction/ activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-1949.
34. Chancey AL et al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002; 105: 1983-1988. (Pubitemid 34437628)
35. Seeland U et al. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol 2002; 34: 151-163. (Pubitemid 35222825)
36. Crow MT et al. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 2004; 95: 957-970. (Pubitemid 39532326)
37. Kim DS et al. The involvement of endoplasmic reticulum stress in flavonoid-induced protection on cardiac cell death caused by ischaemia/reperfusion. J Pharm Pharmacol 2010; 62: 197-204.
38. Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol 2007; 292: C45-C51. (Pubitemid 46115120)
39. Condorelli G et al. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 1999; 99: 3071-3078. (Pubitemid 29270439)
40. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316. (Pubitemid 28406817)
41. Xu J et al. Synergism of simvastatin with losartan prevents angiotensin II-induced cardiomyocyte apoptosis in vitro. J Pharm Pharmacol 2009; 61: 503-510.
42. Chandrashekhar Y et al. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 2004; 43: 295-301. (Pubitemid 38201159)
43. Mohanty IR et al. Bacopa monniera protects rat heart against ischaemia-reperfusion injury: role of key apoptotic regulatory proteins and enzymes. J Pharm Pharmacol 2010; 62: 1175-1184.
44. Song YH et al. Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase-2 and -9 activity and myocardial apoptosis in rats with congestive heart failure. Int J Mol Med 2008; 21: 117-124.